Ono gets exclusive rights to Forty Seven's cancer therapy 5F9
Forty Seven Inc. granted Ono Pharmaceutical Co. Ltd. exclusive rights to develop and sell its anti-CD47 monoclonal antibody 5F9 in Japan, South Korea, Taiwan, and the ASEAN countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam).
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.